To successfully conduct 美国 临床试验 for RCI001, we have completed a business agreement with Ora, a clinical research organization specializing in eye diseases, and are entering full-scale clinical operations.
With the production of 临床试验 raw materials now complete, we are making preparations in close collaboration with Ora to successfully complete 美国 Phase 2 临床试验 in 2022.
Ora, Inc., a 美国-based CRO and SMO specializing in 眼科 diseases, will conduct the 临床试验 using its proprietary CAE™ (Controlled Adverse Environment) model — a more efficient and rapid approach based on extensive experience conducting 干眼症 临床试验.
To successfully complete 美国 临床试验, we have recruited Clinical Team Leader Yuseung Ha, who has years of clinical research experience at IQVIA, and restructured the clinical team as an independent department to build a more agile clinical response environment.